CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Mylan Pharmaceuticals Inc. et al. vs. Regeneron Pharmaceuticals, Inc.

Explore the PTAB proceeding IPR2022-01225 filed by Mylan Pharmaceuticals Inc. et al. on 2022-07-01. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2022-01225

Filing Date

2022-07-01

Accorded Filing Date

2022-07-01

Institution Decision Date

2023-01-11

Last Modified Date

2024-08-23

Proceeding Type

IPR

Termination Date

2024-01-09

Trial Status

Final Written Decision

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 15471506
Respondent Patent Number 10130681
Legal Expiration Date
2037-03-28 Active (10.4 yrs remaining)
Injunction Viability (35 U.S.C. § 283) Active Threat
Respondent Inventor George D. YANCOPOULOS
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

3 Total

Proceeding Status

Final Written Decision

Administrative Patent Judges (APJ Panel)

Panel assignment tracked upon institution decision entry

Board Decisions & Rulings (3)

Voluntarily Dismissed 2024-08-23
Other: Fed Circuit mandate
35 U.S.C. Trial Decision
Final Written Decision 2024-01-09
JUDGMENT Final Written Decision Denying in Part, Granting in Part, and Dismissing in Part Petitioner’s Motion to Exclude Evidence, Denying in Part and Dismissing in Part Patent Owner’s Motion to Exclude Evidence, Determining Challenged Claims 1, 3–11, 13, 14, 16–24, and 26 Unpatentable 35 U.S.C. § 318(a)
37 CFR 42.73, 35 USC 314, 35 USC 318
Institution Granted 2023-01-11
Institution Decision: Grant
35 USC 314

Address and Attorney/Agent Information

23 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name A&P - Regeneron (Prosecution)
Customer Number 191459
Address 601 Massachusetts Ave., NW, Washington, DC, 20001-3743, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
41408 David Marsh +1 202-942-5068
48001 Thomas Triolo +1 914-847-1612
48921 Stephen Gaudet +1 914-847-7376
50370 Neil Miyamoto +1 914-847-7175
50437 Frank Cottingham +1 914-593-1116
58583 Brian Cocca +1 914-847-1421
58714 Ilona Gont +1 914-847-1304
59668 Brandon Schurter +1 914-847-7000

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 18 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 10 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (18): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (10 found):
PTAB: 10
USPTO PTAB Trial 2025-07-14
IPR2025-01269

Fresenius Kabi SwissBiosim, GmbH et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10828345)
Status: Institution Denied
USPTO PTAB Trial 2023-12-18
IPR2024-00298

Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-12-14
IPR2024-00260

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-11-20
IPR2024-00201

Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10888601)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-04-27
IPR2023-00884

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-03-26
IPR2023-00739

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10888601)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-02-10
IPR2023-00532

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2023-02-10
IPR2023-00533

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10888601)
Status: Final Written Decision
USPTO PTAB Trial 2023-02-10
IPR2023-00566

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10888601)
Status: Final Written Decision
USPTO PTAB Trial 2023-01-06
IPR2023-00442

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Final Written Decision
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Proceeding Documents

200
98

Other: Fed Circuit mandate OTHER

2024-08-23 FILING PARTY: BOARD
97

Patent Owner's Notice of Appeal NOTICE

2024-03-12 FILING PARTY: PATENT OWNER
96

JUDGMENT Final Written Decision Denying in Part, Granting in Part, and Dismissing in Part Petitioner’s Motion to Exclude Evidence, Denying in Part and Dismissing in Part Patent Owner’s Motion to Exclude Evidence, Determining Challenged Claims 1, 3–11, 13, 14, 16–24, and 26 Unpatentable 35 U.S.C. § 318(a) FINAL

2024-01-09 FILING PARTY: BOARD
95

Petitioner's Amended Mandatory Notices NOTICE

2023-12-20 FILING PARTY: PETITIONER
94

Petitioner's Amended Mandatory Notices NOTICE

2023-11-29 FILING PARTY: PETITIONER

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc